Analyst Articles

Imagine showing up to a party and find you’re the only one in the room. This is the lonely feeling many companies experience when they complete their initial public offering (IPO). These companies spend a great amount of energy preparing for their debut,… Read More

When one thinks of legendary investors, Peter Lynch stands out as arguably the most successful mutual-fund manager of all time. His track record as manager of Fidelity’s Magellan (Nasdaq: FMAGX) fund is extraordinary. Lynch took control of the Magellan fund in 1977 and grew it into the world’s largest… Read More

When it comes to biotech stocks, some investors like to swing for the fences. When that plan works, it feels great. Shareholders of Dendreon (Nasdaq: DNDN), for example, saw their investment rise from $3 in March 2009 to more than $20 in just two months. The stock has doubled again… Read More

In 1999, James Glassman and Kevin Hassett grabbed headlines with their book Dow 36,000: The New Strategy for Profiting From the Coming Rise in the Stock Market. Their timing was impeccably bad. The Dow Jones Industrial Average peaked later that year at 11,900 and didn’t see the same levels again… Read More